CytoDyn Inc. is a clinical-stage biotechnology company focused on the development and potential commercialization of leronlimab (PRO 140), a humanized monoclonal antibody targeting the CCR5 receptor. The company is studying leronlimab for solid-tumor oncology indications, including microsatellite stable metastatic colorectal cancer and metastatic Triple-Negative Breast Cancer, and is also researching a long-acting version of leronlimab.
Q2 FY2026 — expected 2026-07-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-07-25 | 2025-05-31 | 0001558370-25-009617 | EDGAR | 54K words |
| 2024-08-15 | 2024-05-31 | 0001558370-24-012328 | EDGAR | — |
| 2023-09-14 | 2023-05-31 | 0001558370-23-015718 | EDGAR | — |
| 2022-08-15 | 2022-05-31 | 0001558370-22-013680 | EDGAR | — |
| 2021-07-30 | 2021-05-31 | 0001558370-21-009730 | EDGAR | — |
| 2020-08-14 | 2020-05-31 | 0001193125-20-220598 | EDGAR | — |
| 2019-08-14 | 2019-05-31 | 0001193125-19-221300 | EDGAR | — |
| 2018-07-27 | 2018-05-31 | 0001193125-18-229738 | EDGAR | — |
| 2017-07-20 | 2017-05-31 | 0001193125-17-231500 | EDGAR | — |
| 2016-07-19 | 2016-05-31 | 0001193125-16-651305 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-01-09 | 2025-11-30 | 0001104659-26-002335 | EDGAR | 19K words |
| 2025-10-10 | 2025-08-31 | 0001104659-25-098552 | EDGAR | — |
| 2025-04-14 | 2025-02-28 | 0001558370-25-004774 | EDGAR | — |
| 2025-01-14 | 2024-11-30 | 0001558370-25-000207 | EDGAR | — |
| 2024-10-15 | 2024-08-31 | 0001558370-24-013320 | EDGAR | — |
| 2024-04-15 | 2024-02-29 | 0001558370-24-005134 | EDGAR | — |
| 2024-01-16 | 2023-11-30 | 0001558370-24-000305 | EDGAR | — |
| 2023-10-23 | 2023-08-31 | 0001558370-23-016632 | EDGAR | — |
| 2023-04-10 | 2023-02-28 | 0001558370-23-005695 | EDGAR | — |
| 2023-01-09 | 2022-11-30 | 0001558370-23-000163 | EDGAR | — |
| 2022-10-11 | 2022-08-31 | 0001558370-22-014943 | EDGAR | — |
| 2022-04-11 | 2022-02-28 | 0001558370-22-005291 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001104659-26-033943 | EDGAR | 1K words |
| 2026-03-05 | 0001104659-26-023856 | EDGAR | — |
| 2025-12-01 | 0001104659-25-117154 | EDGAR | — |
| 2025-11-21 | 0001104659-25-115056 | EDGAR | — |
| 2025-11-03 | 0001104659-25-105306 | EDGAR | — |
| 2025-05-16 | 0001558370-25-007954 | EDGAR | — |
| 2025-05-06 | 0001558370-25-006531 | EDGAR | — |
| 2024-11-22 | 0001558370-24-015918 | EDGAR | — |
| 2024-07-09 | 0001558370-24-009701 | EDGAR | — |
| 2024-06-28 | 0001558370-24-009629 | EDGAR | — |
356 total filings indexed. 324 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001175680 |
| Ticker | CYDY |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Vancouver, Washington |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report